This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, E.
Right arrow Articles by Bergeron, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, E.
Right arrow Articles by Bergeron, M. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 1010-1018, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vivo Activity and Pharmacokinetics of Ziracin (SCH27899), a New Long-Acting Everninomicin Antibiotic, in a Murine Model of Penicillin-Susceptible or Penicillin-Resistant Pneumococcal Pneumonia

Erjian Wang, Marie Simard, Yves Bergeron, Denis Beauchamp, and Michel G. Bergeron*

Centre de Recherche en Infectiologie, Université Laval, Sainte-Foy, Québec, Canada G1V 4G2

Received 8 July 1999/Returned for modification 31 October 1999/Accepted 12 January 2000

The effectiveness of ziracin (SCH27899), a novel everninomicin, was at first investigated against lethal pneumonia caused by a penicillin-susceptible Streptococcus pneumoniae strain. A single intravenous injection of ziracin at a dose of 60 mg/kg of body weight given at 18 h postinfection protected 100% mice and led to the complete clearance of bacteria from their lungs. The activity of ziracin was observed to be the same as that of ceftriaxone: the 50% protective doses (PD50s) of ziracin and ceftriaxone were 24.8 and 24.6 mg/kg, respectively. Evaluation of this therapy with leukopenic mice showed that a single injection of ziracin protected 75% of these mice. A delay in therapy with ziracin, which was initiated at 48 h postinfection with 30 mg/kg given once daily for 3 days, resulted in an 83% survival rate of immunocompetent mice. The efficacy of ziracin was further compared to that of vancomycin against lethal pneumonia caused by a penicillin-resistant S. pneumoniae strain in leukopenic mice. The PD50s of ziracin and vancomycin were 40.5 and 44.2 mg/kg, respectively. Treatment with ziracin at 30 mg/kg once daily for 2 days (initiated 18 h postinfection) yielded an 83% survival rate and achieved complete eradication of the bacteria. The results were the same as those obtained with vancomycin administered at 15 mg/kg twice daily for 2 days. It is notable that the high survival rates for mice treated with ziracin were associated with effective eradication of the bacteria and rapid recovery of pulmonary tissues from pneumonia. The pharmacokinetic properties of ziracin, ceftriaxone, and vancomycin were estimated following intravenous administration of a single dose of 30 mg/kg to immunocompetent mice. The half-life of ziracin was observed to be longer than those of ceftriaxone and vancomycin (2.3 h versus 1.0 and 0.36 h in the bloodstream and 3 h versus 1.9 and 0.45 h in lung tissues). The areas under the concentration-time curves (AUCs) in lung tissue for ziracin versus those for ceftriaxone and vancomycin were 36 µg · h/g versus 20 and 9.5 µg · h/g. The prolonged half-life and high AUC for ziracin in tissue contributed to its excellent in vivo activities.

* Corresponding author. Mailing address: Centre de Recherche en Infectiologie, Centre Hospitalier de l'Université Laval, 2705 Boul. Laurier, Sainte-Foy, Québec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: Michel.G.Bergeron{at}crchul.ulaval.ca.

Antimicrobial Agents and Chemotherapy, April 2000, p. 1010-1018, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Wang, E., Bergeron, Y., Bergeron, M. G. (2005). Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia. J Antimicrob Chemother 55: 721-726 [Abstract] [Full Text]  
  • Wang, E., Simard, M., Ouellet, N., Bergeron, Y., Beauchamp, D., Bergeron, M. G. (2002). Pathogenesis of Pneumococcal Pneumonia in Cyclophosphamide-Induced Leukopenia in Mice. Infect. Immun. 70: 4226-4238 [Abstract] [Full Text]  
  • Weitnauer, G., Gaisser, S., Kellenberger, L., Leadlay, P. F., Bechthold, A. (2002). Analysis of a C-methyltransferase gene (aviG1) involved in avilamycin biosynthesis in Streptomyces viridochromogenes Tu57 and complementation of a Saccharopolyspora erythraea eryBIII mutant by aviG1. Microbiology 148: 373-379 [Abstract] [Full Text]  
  • Pavia, C., Inchiosa, M. A. Jr, Wormser, G. P. (2002). Efficacy of Short-Course Ceftriaxone Therapy for Borrelia burgdorferi Infection in C3H Mice. Antimicrob. Agents Chemother. 46: 132-134 [Abstract] [Full Text]  
  • Weitnauer, G., Gaisser, S., Trefzer, A., Stockert, S., Westrich, L., Quiros, L. M., Mendez, C., Salas, J. A., Bechthold, A. (2001). An ATP-Binding Cassette Transporter and Two rRNA Methyltransferases Are Involved in Resistance to Avilamycin in the Producer Organism Streptomyces viridochromogenes Tu57. Antimicrob. Agents Chemother. 45: 690-695 [Abstract] [Full Text]  
  • Pavia, C. S., Wormser, G. P., Nowakowski, J., Cacciapuoti, A. (2001). Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease. Antimicrob. Agents Chemother. 45: 936-937 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»